Contineum Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Contineum Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CTNM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001855175
- EIN
- 27-1467257
Board of directors
-
Carmine N. Stengone · Director · CEO and PresidentSince 2024
-
Evert B. Schimmelpennink · DirectorSince 2024
-
Gines Diego Miralles · DirectorSince 2025
-
Lori Lyons-Williams · DirectorSince 2024
-
Olivia C. Ware · DirectorSince 2024
-
Sarah Boyce · DirectorSince 2024
-
Todd R. Brady · DirectorSince 2024
-
Troy A. Ignelzi · DirectorSince 2024
Chief executives
Carmine N. Stengone
· CEO and President
Since April 2024
Director election results
Annual meeting of June 26, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
94.0%
-
99.4%
Board connections
5 of this board's directors also sit on 7 other boards.
- via Gines Diego Miralles
- via Sarah Boyce
- via Troy A. Ignelzi
- via Carmine N. Stengone
- via Evert B. Schimmelpennink
- via Sarah Boyce
- via Evert B. Schimmelpennink
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,858,351
- 31 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Option exercise | +2,500 | $1.01 | $2,525 |
| Sep 8, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Open-market sale | −2,500 | $16.46 | $41,142 |
| Aug 3, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Option exercise | +2,500 | $1.01 | $2,525 |
| Aug 3, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Open-market sale | −2,500 | $16.01 | $40,029 |
| Jul 9, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Option exercise | +25 | $1.01 | $25 |
| Jul 9, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Open-market sale | −25 | $16.00 | $400 |
| Jul 8, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Option exercise | +2,500 | $1.01 | $2,525 |
| Jul 8, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Option exercise | +1,015 | $1.01 | $1,025 |
| Jul 8, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Open-market sale | −2,500 | $16.00 | $40,000 |
| Jul 8, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Open-market sale | −1,015 | $16.00 | $16,240 |
| Jul 1, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Option exercise | +4,183 | $1.01 | $4,225 |
| Jul 1, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Open-market sale | −5,852 | $15.67 | $91,682 |
| Jul 1, 2026 | Lorrain Daniel S. Officer (Chief Scientific Officer) | Open-market sale | −2,501 | $16.24 | $40,608 |
| Jun 30, 2026 | Carmine N. Stengone Director, Officer (CEO and President) | Option exercise | +7,500 | $1.01 | $7,575 |
| Jun 30, 2026 | Watkins Tim Officer (CMO & Head of Development) | Option exercise | +10,833 | $4.50 | $48,749 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.